# EDGAR Filing Document

**Accession Number:** 0000822663
**File Stem:** 0001753926-26-000771
**Filing Date:** 2026-5
**Character Count:** 98540
**Document Hash:** 37b6101292e047269c4348faacb0353b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001753926-26-000771.hdr.sgml**: 20260505

**ACCESSION NUMBER**: 0001753926-26-000771

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 52

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260505

**DATE AS OF CHANGE**: 20260505

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** INTERPARFUMS INC
- **CENTRAL INDEX KEY:** 0000822663
- **STANDARD INDUSTRIAL CLASSIFICATION:** PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS [2844]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 133275609
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-16469
- **FILM NUMBER:** 26943765

**BUSINESS ADDRESS:**
- **STREET 1:** 551 FIFTH AVE
- **STREET 2:** STE 1500
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10176
- **BUSINESS PHONE:** 2129832640

**MAIL ADDRESS:**
- **STREET 1:** 551 FIFTH AVENUE
- **STREET 2:** STE 1500
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10176

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** INTER PARFUMS INC
- **DATE OF NAME CHANGE:** 19990715

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** JEAN PHILIPPE FRAGRANCES INC
- **DATE OF NAME CHANGE:** 19920703

?xml version='1.0' encoding='ASCII'? ipar-20260331.htm

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 10-Q**

**(MARK ONE)**

**☒** Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended March 31, 2026.

**OR**

☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from ___________to ________.

Commission File No. **<u>0-16469</u>**

***INTERPARFUMS, INC.***

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Delaware** | **13-3275609** |
| (State or other jurisdiction of | (I.R.S. Employer |
| incorporation or organization) | Identification No.) |

---

---

| |
|:---|
| **551 Fifth Avenue, New York, New York 10176** |
| (Address of Principal Executive Offices)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (Zip Code) |

---

---

| |
|:---|
| **(212) 983-2640** |
| (Registrants telephone number, including area code) |

---

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, $.001 par value per share | IPAR | The Nasdaq Stock Market |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days: Yes **☒** No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes **☒** No **☐**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act).

---

| | |
|:---|:---|
| &nbsp;&nbsp;Large accelerated filer ☒ | &nbsp;&nbsp;Accelerated filer ☐ |
| &nbsp;&nbsp;Non-accelerated filer ☐ (Do not check if a smaller reporting company) | &nbsp;&nbsp;Smaller reporting company ☐ |
|  | &nbsp;&nbsp;Emerging Growth company ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes **☐** No **☒**

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

At May 5, 2026, there were 32,025,781 shares of common stock, par value $.001 per share, outstanding.

------

***INTERPARFUMS, INC. AND SUBSIDIARIES***

**INDEX**

---

| | | | |
|:---|:---|:---|:---|
|  |  |  | Page Number  |
| [Part I.](#BRN1_1462024194129560) | [Financial Information](#BRN1_1462024194129560) | [Financial Information](#BRN1_1462024194129560) | 1 |
|  | [Item 1.](#BRN2_146202419426753) | [Financial Statements](#BRN2_146202419426753) | 1 |
|  |  | [Consolidated Balance Sheets as of March 31, 2026 and December 31, 2025](#BRN3_146202419434645) | 2 |
|  |  | [Consolidated Statements of Income for the Three Months Ended March 31, 2026 and March 31, 2025](#BRN4_1462024194330786) | 3 |
|  |  | [Consolidated Statements of Comprehensive Income for the Three Months Ended March 31, 2026 and March 31, 2025](#BRN5_1462024194414665) | 4 |
|  |  | [Consolidated Statements of Changes in Equity for the Three Months Ended March 31, 2026 and March 31, 2025](#BRN6_1462024194556690) | 5 |
|  |  | [Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2026 and March 31, 2025](#BRN7_1462024194633562) | 6 |
|  |  | [Notes to Consolidated Financial Statements](#BRN8_1462024194735586) | 7 |
|  | [Item 2.](#BBRN9_272024114355882) | [Management's Discussion and Analysis of Financial Condition and Results of Operations](#BBRN9_272024114355882) | 17 |
|  | [Item 3.](#BRN10_146202419492549) | [Quantitative and Qualitative Disclosures About Market Risk](#BRN10_146202419492549) | 25 |
|  | [Item 4.](#BRN11_1462024194913564) | [Controls and Procedures](#BRN11_1462024194913564) | 25 |
| [Part II.](#BRN12_146202419494757) | [Other Information](#BRN12_146202419494757) | [Other Information](#BRN12_146202419494757) | 26 |
|  | [Item 1A.](#BItem_1A_41020251333367) | [Risk Factors](#BItem_1A_41020251333367) | 26 |
|  | [Item 2.](#BRN13_146202419501178) | [Unregistered Sales of Equity Securities and Use of Proceeds.](#BRN13_146202419501178) | 26 |
|  | [Item 5.](#BRN14_1462024195015817) | [Other Information](#BRN14_1462024195015817) | 26 |
|  | [Item 6.](#BRN15_1462024195037528) | [Exhibits.](#BRN15_1462024195037528) | 27 |
| [SIGNATURES](#BRN16_146202419513640) | [SIGNATURES](#BRN16_146202419513640) | [SIGNATURES](#BRN16_146202419513640) | 28 |

---

------

***INTERPARFUMS, INC. AND SUBSIDIARIES***

[**Part I. Financial Information**](#TOC)

---

| | |
|:---|:---|
| **Item** **1.** | [**Financial Statements**](#TOC) |

---

In our opinion, the accompanying unaudited consolidated financial statements contain all adjustments (consisting only of normal recurring adjustments) necessary to present fairly our financial position, results of operations and cash flows for the interim periods presented. We have condensed such financial statements in accordance with the rules and regulations of the Securities and Exchange Commission ("SEC"). Therefore, such financial statements do not include all disclosures required by accounting principles generally accepted in the United States of America. In preparing these consolidated financial statements, the Company has evaluated events and transactions for potential recognition or disclosure through the date the consolidated financial statements were issued by filing with the SEC. These financial statements should be read in conjunction with our audited financial statements for the year ended December 31, 2025, included in our annual report filed on Form 10-K.

The results of operations for the three months ended March 31, 2026, are not necessarily indicative of the results to be expected for the entire fiscal year.

------

***INTERPARFUMS, INC. AND SUBSIDIARIES***

**[CONSOLIDATED BALANCE SHEETS](#TOC)**

(In thousands except share and per share data)

 *(Unaudited)*

---

| | | |
|:---|:---|:---|
| ***ASSETS*** |  |  |
|  | **March 31, 2026** | **December 31, 2025** |
| **Current assets:** |  |  |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | $79864 | $158091 |
| &nbsp;&nbsp;&nbsp;Short-term investments | 157206 | 137093 |
| &nbsp;&nbsp;&nbsp;Accounts receivable, net | 332731 | 320625 |
| &nbsp;&nbsp;&nbsp;Inventories | 369630 | 351377 |
| &nbsp;&nbsp;&nbsp;Receivables, other | 5853 | 9014 |
| &nbsp;&nbsp;&nbsp;Other current assets | 44669 | 39954 |
| &nbsp;&nbsp;&nbsp;Income taxes receivable | 7814 | 11211 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 997767 | 1027365 |
| **Property, equipment and leasehold improvements, net** | 179389 | 184891 |
| **Right-of-use assets, net** | 22229 | 23347 |
| **Trademarks, licenses and other intangible assets, net** | 317032 | 325185 |
| **Deferred tax assets** | 5311 | 4234 |
| **Other assets** | 21055 | 20226 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total assets** | $1542783 | $1585248 |
| ***LIABILITIES AND EQUITY*** |  |  |
| **Current liabilities:** |  |  |
| &nbsp;&nbsp;&nbsp;Loans payable - banks | $4599 | $9400 |
| &nbsp;&nbsp;&nbsp;Current portion of long-term debt | 50158 | 54774 |
| &nbsp;&nbsp;&nbsp;Current portion of lease liabilities | 6212 | 6326 |
| &nbsp;&nbsp;&nbsp;Accounts payable – trade | 85342 | 77210 |
| &nbsp;&nbsp;&nbsp;Accrued expenses | 150836 | 189622 |
| &nbsp;&nbsp;&nbsp;Income taxes payable | 8781 | 6671 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 305928 | 344003 |
| **Long–term debt, less current portion** | 107190 | 121254 |
| **Lease liabilities, less current portion** | 14609 | 15967 |
| **Deferred tax liabilities** | 2504 |  |
| **Equity:** |  |  |
| &nbsp;&nbsp;&nbsp;Interparfums, Inc. shareholders' equity: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Preferred stock, $.001 par; authorized 1,000,000 shares; none issued |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Common stock, $.001 par; authorized 100,000,000 shares; outstanding 32,025,781 and 32,067,285 shares at March 31, 2026 and December 31, 2025, respectively | 32 | 32 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additional paid-in capital | 127503 | 127541 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Retained earnings | 846631 | 828906 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accumulated other comprehensive loss | (21853) | (9029) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Treasury stock, at cost, 9,078,844 and 9,032,840 shares at March 31, 2026 and December 31, 2025, respectively | (70670) | (66734) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Interparfums, Inc. shareholders' equity | 881643 | 880716 |
| &nbsp;&nbsp;&nbsp;Noncontrolling interest | 230909 | 223308 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total equity | 1112552 | 1104024 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total liabilities and equity** | $1542783 | $1585248 |

---

*See notes to consolidated financial statements.*

------

***INTERPARFUMS, INC. AND SUBSIDIARIES***

[***CONSOLIDATED STATEMENTS OF INCOME***](#TOC)

(In thousands except per share data)

 *(Unaudited)*

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** |
|  | **March 31,** | **March 31,** |
|  | **2026** | **2025** |
| **Net sales** | $344885 | $338819 |
| **Cost of sales** | 120246 | 122842 |
| **Gross margin** | 224639 | 215977 |
| **Selling, general and administrative expenses** | 150505 | 140900 |
| **Income from operations** | 74134 | 75077 |
| **Other expenses (income):** |  |  |
| &nbsp;&nbsp;&nbsp;Interest expense | 1434 | 1545 |
| &nbsp;&nbsp;&nbsp;Loss on foreign currency | 102 | 781 |
| &nbsp;&nbsp;&nbsp;Interest and investment income | (2318) | (581) |
| &nbsp;&nbsp;&nbsp;Other income | (290) | (79) |
| **Nonoperating Income (Expense)** | (1072) | 1666 |
| **Income before income taxes** | 75206 | 73411 |
| Income taxes | 18503 | 18008 |
| **Net income** | 56703 | 55403 |
| &nbsp;&nbsp;&nbsp;Less: Net income attributable to the noncontrolling interest | 13337 | 12911 |
| **Net income attributable to Interparfums, Inc.** | $43366 | $42492 |
| **Earnings per share:** |  |  |
| **Net income attributable to Interparfums, Inc. common shareholders:** |  |  |
| &nbsp;&nbsp;&nbsp;Basic | $1.35 | $1.32 |
| &nbsp;&nbsp;&nbsp;Diluted | $1.35 | $1.32 |
| **Weighted average number of shares outstanding:** |  |  |
| &nbsp;&nbsp;&nbsp;Basic | 32028 | 32121 |
| &nbsp;&nbsp;&nbsp;Diluted | 32028 | 32174 |
| **Dividends declared per share** | $0.80 | $0.80 |

---

*See notes to consolidated financial statements.*

------

***INTERPARFUMS, INC. AND SUBSIDIARIES***

[***CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME***](#TOC)

(In thousands)

*(Unaudited)*

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** |
|  | **March 31,** | **March 31,** |
|  | **2026** | **2025** |
| **Comprehensive income:** |  |  |
| &nbsp;&nbsp;&nbsp;Net income | $56703 | $55403 |
| &nbsp;&nbsp;&nbsp;Other comprehensive income: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net derivative instrument gain, net of tax | 73 | 4333 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transfer from OCI into earnings | (912) | 1631 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pension benefits, net of tax | (55) | (50) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign currency translation adjustments | (17160) | 27922 |
| **Comprehensive income** | 38649 | 89239 |
| **Comprehensive income attributable to the noncontrolling interests:** |  |  |
| &nbsp;&nbsp;&nbsp;Net income | 13337 | 12911 |
| &nbsp;&nbsp;&nbsp;Other comprehensive income: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net derivative instrument gain, net of tax | 20 | 1191 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pension benefits, net of tax | (15) | (14) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign currency translation adjustments | (5235) | 7274 |
| **Comprehensive income attributable to the noncontrolling interests** | 8107 | 21362 |
| **Comprehensive income attributable to Interparfums, Inc.** | $30542 | $67877 |

---

*See notes to consolidated financial statements.*

------

***INTERPARFUMS, INC. AND SUBSIDIARIES***

[***CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY***](#TOC)

(In thousands)

*(Unaudited)*

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** |
|  | **March 31,** | **March 31,** |
|  | **2026** | **2025** |
| **Common stock, beginning and end of period** | $32 | $32 |
| **Additional paid-in capital, beginning of period** | 127541 | 106702 |
| &nbsp;&nbsp;&nbsp;Shares issued upon exercise of stock options | 280 | 1077 |
| &nbsp;&nbsp;&nbsp;Share-based compensation | 244 | 206 |
| &nbsp;&nbsp;&nbsp;Other | (562) |  |
| **Additional paid-in capital, end of period** | 127503 | 107985 |
| **Retained earnings, beginning of period** | 828906 | 763240 |
| &nbsp;&nbsp;&nbsp;Net income | 43366 | 42492 |
| &nbsp;&nbsp;&nbsp;Dividends | (25641) | (25700) |
| &nbsp;&nbsp;&nbsp;Share-based compensation |  | 306 |
| **Retained earnings, end of period** | 846631 | 780338 |
| **Accumulated other comprehensive loss, beginning of period** | (9029) | (72239) |
| &nbsp;&nbsp;&nbsp;Foreign currency translation adjustment | (11925) | 20648 |
| &nbsp;&nbsp;&nbsp;Transfer from other comprehensive income into earnings | (912) | 1631 |
| &nbsp;&nbsp;&nbsp;Pension benefits, net of tax | (40) | (36) |
| &nbsp;&nbsp;&nbsp;Net derivative instrument gain, net of tax | 53 | 3142 |
| **Accumulated other comprehensive loss, end of period** | (21853) | (46854) |
| **Treasury stock, beginning of period** | (66734) | (52864) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares repurchased | (3936) |  |
| **Treasury stock, end of period** | (70670) | (52864) |
| **Noncontrolling interest, beginning of period** | 223308 | 197774 |
| &nbsp;&nbsp;&nbsp;Net income | 13337 | 12911 |
| &nbsp;&nbsp;&nbsp;Foreign currency translation adjustment | (5235) | 7274 |
| &nbsp;&nbsp;&nbsp;Pension benefits, net of tax | (15) | (14) |
| &nbsp;&nbsp;&nbsp;Net derivative instrument gain, net of tax | 20 | 1191 |
| &nbsp;&nbsp;&nbsp;Share-based compensation | 180 | 55 |
| &nbsp;&nbsp;&nbsp;Transfer of subsidiary shares purchased | (1248) |  |
| &nbsp;&nbsp;&nbsp;Other | 562 |  |
| &nbsp;&nbsp;&nbsp;Dividends |  | (309) |
| **Noncontrolling interest, end of period** | 230909 | 218882 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total equity** | $1112552 | $1007519 |

---

*See notes to consolidated financial statements.*

------

***INTERPARFUMS, INC. AND SUBSIDIARIES***

[***CONSOLIDATED STATEMENTS OF CASH FLOWS***](#TOC)

(In thousands)

*(Unaudited)*

---

| | | |
|:---|:---|:---|
|  | Three Months Ended | Three Months Ended |
|  | **March 31,** | **March 31,** |
|  | 2026 | 2025 |
| **Cash flows from operating activities:** |  |  |
| &nbsp;&nbsp;&nbsp;Net income | $56703 | $55403 |
| &nbsp;&nbsp;&nbsp;Adjustments to reconcile net income to net cash used in operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 5799 | 5927 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Provision for doubtful accounts | 837 | (36) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Noncash stock compensation | 425 | 559 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Share of income of equity investment | (290) | (79) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Noncash lease expense | 1609 | 1745 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred tax provision | 1388 | 1524 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in fair value of derivatives | 889 | (2415) |
| &nbsp;&nbsp;&nbsp;Changes in: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable | (18766) | (20774) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories | (24428) | (12252) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other assets | (3889) | 247 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating lease liabilities | (1695) | (1851) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable and accrued expenses | (23874) | (42539) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income taxes, net | 5377 | 7183 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by (used in) operating activities | 85 | (7358) |
| **Cash flows from investing activities:** |  |  |
| &nbsp;&nbsp;&nbsp;Purchases of short-term investments | (105486) | (31653) |
| &nbsp;&nbsp;&nbsp;Proceeds from sale of short-term investments | 82021 | 69097 |
| &nbsp;&nbsp;&nbsp;Purchases of property, equipment and leasehold improvements | (1363) | (1440) |
| &nbsp;&nbsp;&nbsp;Payment for intangible assets acquired | (1775) | (22495) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash (used in) provided by investing activities | (26603) | 13509 |
| **Cash flows from financing activities:** |  |  |
| &nbsp;&nbsp;&nbsp;Proceeds from loans payable, bank | (4682) | (1052) |
| &nbsp;&nbsp;&nbsp;Repayment of long-term debt | (15167) | (12451) |
| &nbsp;&nbsp;&nbsp;Proceeds from exercise of options | 280 | 1077 |
| &nbsp;&nbsp;&nbsp;Dividends paid | (25641) | (25700) |
| &nbsp;&nbsp;&nbsp;Dividends paid to noncontrolling interest |  | (309) |
| &nbsp;&nbsp;&nbsp;Purchase of subsidiary shares from noncontrolling interests | (1248) |  |
| &nbsp;&nbsp;&nbsp;Purchase of treasury stock | (3936) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in financing activities | (50394) | (38435) |
| **Effect of exchange rate changes on cash** | (1315) | 3468 |
| **Net decrease in cash and cash equivalents**  | (78227) | (28816) |
| Cash and cash equivalents - beginning of period | 158091 | 125433 |
| **Cash and cash equivalents - end of period** | $79864 | $96617 |
| **Supplemental disclosure of cash flow information:** |  |  |
| &nbsp;&nbsp;&nbsp;Cash paid for: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest | $1346 | $1401 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income taxes | 12129 | 9475 |

---

*See notes to consolidated financial statements.* 

------

***INTERPARFUMS, INC. AND SUBSIDIARIES***

[**Notes to Consolidated Financial Statements**](#TOC)

*(Unaudited)* 

**1.** **<u>Significant Accounting Policies:</u>**

The accounting policies we follow are set forth in the notes to our consolidated financial statements included in our Form 10-K, which was filed with the Securities and Exchange Commission for the year ended December 31, 2025.

**2.** **<u>Recent Agreements:</u>**

***Nautica***

**In January 2026, we entered into a 20-year license agreement for Nautica brand fragrances and fragrance related products, a subsidiary of the Authentic Brands Group. Our rights under this license are subject to certain minimum advertising expenditures and royalty payments as are customary in our industry. Interparfums will assume full global responsibility for Nautica fragrances effective January 1, 2030.** 

***David Beckham***

**In January 2026, we entered into a 20-year license agreement for David Beckham brand fragrances and fragrance related products, a subsidiary of the Authentic Brands Group. This license will become effective on April 1, 2028. Our rights under this license are subject to certain minimum advertising expenditures and royalty payments as are customary in our industry.** 

*GUESS*

In 2018, GUESS?, Inc. and the Company signed an exclusive worldwide license agreement for the creation, the manufacturing and the distribution of fragrances under the GUESS brand until December 31, 2033. In December 2025, the license agreement was renewed for an additional 15 years, extending the license through December 31, 2048.

***Longchamp***

In July 2025, we announced that our 72% owned French subsidiary, Interparfums SA, signed an exclusive license agreement with Longchamp, a Parisian Maison, through December 31, 2036. Interparfums SA will be responsible for the creation, development, production and distribution of fragrance lines in Longchamp-brand points of sale and selective distribution channels. The first launch is expected in 2027. Our rights under this license are subject to certain minimum advertising expenditures and royalty payments as are customary in our industry.

***Goutal***

In March 2025, we announced that our 72% owned French subsidiary, Interparfums SA, acquired all intellectual property rights relating to Goutal Paris held by Amorepacific Europe. In January 2026, Interparfums SA began commercial use of the fragrance brand.

***Coach***

**In 2015, Coach and Interparfums SA signed an exclusive worldwide license agreement for the creation, the manufacturing and the distribution of fragrances under the Coach brand until June 30, 2026. In March 2025, the license agreement was renewed for an additional 5-year term, extending the license through June 30, 2031.** 

***Abercrombie & Fitch and Hollister***

In March 2025, we expanded our *Fierce* distribution agreement, which now allows for a global distribution of the iconic *Fierce* fragrance line that either party may terminate on two year's notice. Furthermore, our existing Abercrombie & Fitch and Hollister fragrance license agreement will expire on March 14, 2028. The goal of the updated *Fierce* distribution agreement is to drive, over time, more consistency between the products that are carried in the Abercrombie & Fitch stores and unaffiliated retailers.

------

***INTERPARFUMS, INC. AND SUBSIDIARIES***

 ***Notes to Consolidated Financial Statements***

***Rochas Fashion***

As a result of operational challenges faced by the Rochas Fashion business, we have taken impairment charges on our Rochas fashion trademark, and in the fourth quarter of 2024, management reviewed and agreed with an independent expert's conclusion that the fair value of the trademark was $7.2 million. There have been no triggering events in the first quarter of 2026 and 2025 that would require management to perform an impairment analysis.

**3.** **<u>Recent Accounting Pronouncements:</u>**

In November 2024, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses and in January 2025, the FASB issued ASU No. 2025-01, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date, which clarified the effective date of ASU 2024-03. The ASU requires, among other things, more detailed disclosures about types of expenses in commonly presented expense captions such as cost of sales and selling, general and administrative expenses and is intended to improve the disclosures about an entity's expenses including purchases of inventory, employee compensation, depreciation and intangible asset amortization. ASU 2024-03 will also require the Company to disclose both the amount and the Company's definition of selling expenses. The guidance, as clarified by ASU 2025-01, is effective for fiscal years beginning after December 15, 2026, and interim periods for fiscal years beginning after December 15, 2027, on a prospective or retrospective basis. Early adoption is permitted. We are currently evaluating the impact of adopting this ASU on our disclosures.

In November 2025, the FASB issued ASU 2025-09, Derivatives and Hedging (Topic 815): Hedge Accounting Improvements. The guidance makes targeted amendments to the hedge accounting model to better align the accounting with an entity's risk management activities and to clarify the application of certain hedge accounting requirements. The amendments are effective for the Company for fiscal years beginning after December 15, 2026, including interim periods, with early adoption permitted. The Company is currently evaluating the impact of adopting this guidance on its hedge accounting policies and disclosures; however, the Company does not expect adoption to have a material impact on its consolidated financial position, results of operations, or cash flows.

There are no other recent accounting pronouncements issued but not yet adopted that would have a material effect on our consolidated financial statements.

**4.** **<u>Inventories:</u>**

Inventories consist of the following:

---

| | | |
|:---|:---|:---|
| (In thousands) | **March 31, 2026** | **December 31, 2025** |
| Raw materials and component parts | $132378 | $129706 |
| Finished goods | 237252 | 221671 |
|  | $369630 | $351377 |

---

------

***INTERPARFUMS, INC. AND SUBSIDIARIES***

**Notes to Consolidated Financial Statements**

**5.** **<u>Fair Value Measurement:</u>**

The following tables present our financial assets and liabilities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy. The fair value hierarchy has three levels based on the reliability of the inputs used to determine fair value.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  |  | **Fair Value Measurements at March 31, 2026** | **Fair Value Measurements at March 31, 2026** | **Fair Value Measurements at March 31, 2026** |
|  | **Total** | **Quoted Prices in<br> Active Markets for<br> Identical Assets<br> (Level 1)** | **Significant Other<br> Observable<br> Inputs<br> (Level 2)** | **Significant<br> Unobservable<br> Inputs<br> (Level 3)** |
| Assets: |  |  |  |  |
| &nbsp;&nbsp;Short-term investments | $157206 | $3621 | $153585 | $— |
| &nbsp;&nbsp;Interest rate swaps | 2113 |  | 2113 |  |
| &nbsp;&nbsp;Total Assets | $159319 | $3621 | $155698 | $— |
| Liabilities: |  |  |  |  |
| &nbsp;&nbsp;Interest rate swaps | $26 | $— | $26 | $— |
| &nbsp;&nbsp;Foreign currency forward exchange contracts not accounted for using hedge accounting | 386 |  | 386 |  |
| &nbsp;&nbsp;Total Liabilities | $412 | $— | $412 | $— |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  |  | **Fair Value Measurements at December 31, 2025** | **Fair Value Measurements at December 31, 2025** | **Fair Value Measurements at December 31, 2025** |
|  | **Total** | **Quoted Prices in<br> Active Markets for<br> Identical Assets<br> (Level 1)** | **Significant Other<br> Observable<br> Inputs<br> (Level 2)** | **Significant<br> Unobservable<br> Inputs<br> (Level 3)** |
| Assets: |  |  |  |  |
| &nbsp;&nbsp;Short-term investments | $137093 | $3801 | $133292 | $— |
| &nbsp;&nbsp;Interest rate swaps | 1597 |  | 1597 |  |
| &nbsp;&nbsp;Foreign currency forward exchange contracts not accounted for using hedge accounting | 498 |  | 498 |  |
| &nbsp;&nbsp;Foreign currency forward exchange contracts accounted for using hedge accounting | 169 |  | 169 |  |
| &nbsp;&nbsp;Total Assets | $139357 | $3801 | $135556 | $— |

---

------

***INTERPARFUMS, INC. AND SUBSIDIARIES***

**Notes to Consolidated Financial Statements**

The carrying amount of cash and cash equivalents, short-term investments including money market funds and marketable equity securities, accounts receivable, other receivables, accounts payable and accrued expenses approximate fair value due to the short terms to maturity of these instruments. The carrying amount of loans payable approximates fair value as the interest rates on the Company's indebtedness approximate current market rates. The fair value of the Company's long-term debt was estimated based on the current rates offered to companies for debt with the same remaining maturities and is approximately equal to its carrying value.

Foreign currency forward exchange contracts are valued based on quotations from financial institutions and the value of interest rate swaps is the discounted net present value of the swaps using third party quotes from financial institutions.

**6.** **<u>Derivative Financial Instruments:</u>**

The Company enters into foreign currency forward exchange contracts to hedge exposure related to receivables denominated in a foreign currency and occasionally to manage risks related to future sales expected to be denominated in a foreign currency. Before entering into a derivative transaction for hedging purposes, we determine that a high degree of initial effectiveness exists between the change in value of the hedged item and the change in the value of the derivative instrument from movement in exchange rates. High effectiveness means that the change in the cash flows of the derivative instrument will effectively offset the change in the cash flows of the hedged item. The effectiveness of each hedged item is measured throughout the hedged period and is based on the dollar offset methodology and excludes the portion of the fair value of the foreign currency forward exchange contract attributable to the change in spot-forward difference which is reported in current period earnings. Any hedge ineffectiveness is also recognized as a gain or loss on foreign currency in the income statement. For contracts designated as hedges that are no longer deemed highly effective, hedge accounting is discontinued, and gains and losses accumulated in other comprehensive income are reclassified to earnings. If it is probable that the forecasted transaction will no longer occur, then any gains or losses accumulated in other comprehensive income are reclassified to current-period earnings.

In December 2022, to finance the acquisition of the Lacoste trademark, the Company entered into a €50 million (approximately $57.5 million) 4-year term loan with a variable interest rate. This variable rate debt was swapped for variable interest rate debt with a maximum rate of 2% per annum. This swap is a hedged derivative instrument and is therefore recorded at fair value and changes in fair value are reflected in the accompanying consolidated statements of comprehensive income.

In connection with the April 2021 acquisition of the office building complex in Paris, €120 million (approximately $138.0 million) of the purchase price was financed through a 10-year variable rate term loan. The Company entered into interest rate swap contracts related to €80 million of the loan, effectively exchanging the variable interest rate to a fixed rate of approximately 1.1%. This derivative instrument is recorded at fair value and changes in fair value are reflected in the accompanying consolidated statements of income.

Gains and losses in derivatives designated as hedges are accumulated in other comprehensive income and gains and losses in derivatives not designated as hedges are included in loss on foreign currency in the accompanying consolidated statements of income. Such gains and losses were immaterial for the three months ended March 31, 2026 and 2025, respectively.

All derivative instruments are reported as either assets or liabilities on the consolidated balance sheet measured at fair value. The fair value of interest rate swaps includes a liability position, which is included in long-term debt on the accompanying consolidated balance sheet, and an asset position, which is included in other assets on the accompanying balance sheet. The fair value of foreign currency forward exchange contracts at March 31, 2026, resulted in a net liability and is included in accrued expenses on the accompanying consolidated balance sheet.

At March 31, 2026, the Company had foreign currency contracts in the form of forward exchange contracts with notional amounts of approximately USD $38.0 million, all of which have maturities of less than one year.

------

***INTERPARFUMS, INC. AND SUBSIDIARIES***

**Notes to Consolidated Financial Statements**

**7.** **<u>Leases:</u>**

The Company leases its offices and warehouses, vehicles, and certain office equipment, substantially all of which are classified as operating leases. The Company currently has no material financing leases. The Company determines if an arrangement is a lease at inception. Operating lease assets and obligations are recognized at the lease commencement date based on the present value of lease payments over the lease term.

In determining lease asset value, the Company considers fixed or variable payment terms, prepayments, incentives, and options to extend or terminate, depending on the lease. Renewal, termination or purchase options affect the lease term used for determining lease asset value only if the option is reasonably certain to be exercised. The Company generally uses its incremental borrowing rate based on information available at the lease commencement date for the location in which the lease is held in determining the present value of lease payments.

As of March 31, 2026, the weighted average remaining lease term was 3.3 years and the weighted average discount rate used to determine the operating lease liability was 3.2%. Rental expense related to operating leases was $1.7 million and $1.6 million for the threemonths ended March 31, 2026 and 2025, respectively. Operating lease payments included in operating cash flows totaled $1.7 million and $1.9 million for the March 31, 2026 and 2025, respectively, and noncash additions to operating lease assets totaled $0.4 million and $0.03 million for the March 31, 2026 and 2025, respectively.

**8.** **<u>Share-Based Payments:</u>**

The Company maintains a stock option program for key employees, executives and directors. The plans, all of which have been approved by shareholder vote, provide for the granting of both nonqualified and incentive options. Options granted under the plans typically have a six-year term and vest over a five-year period. The fair value of shares vested during the March 31, 2026 and 2025 aggregated $0.0 million and $0.02 million, respectively. Compensation cost, net of estimated forfeitures, is recognized on a straight-line basis over the requisite service period for the entire award. Forfeitures are estimated based on historic trends. It is generally our policy to issue new shares upon exercise of stock options.

The following table sets forth information with respect to nonvested options for the March 31, 2026:

---

| | | |
|:---|:---|:---|
|  | **Number of Shares** | **Weighted Average Grant-Date Fair Value** |
| Nonvested options at January 1, 2026 | 131600 | $26.83 |
| Nonvested options granted |  |  |
| Nonvested options vested or forfeited | (2000) | $29.96 |
| Nonvested options at March 31, 2026 | 129600 | $26.78 |

---

------

***INTERPARFUMS, INC. AND SUBSIDIARIES***

**Notes to Consolidated Financial Statements**

Share-based payment expense decreased income before income taxes by $0.42 million and $0.56 million for the three months ended March 31, 2026 and 2025, respectively, and decreased income attributable to Interparfums, Inc. by $0.29 million and $0.36 million for the three months ended March 31, 2026 and 2025 respectively, for the corresponding periods of the prior year.

The following table summarizes stock option information as of March 31, 2026:

---

| | | |
|:---|:---|:---|
|  | **Shares** | **Weighted Average<br> Exercise Price** |
| Outstanding at January 1, 2026 | 187050 | $112.67 |
| Options forfeited | (2900) | 126.33 |
| Options exercised | (4500) | 62.18 |
| Outstanding at March 31, 2026 | 179650 | $113.72 |
| Options exercisable | 50050 | $120.17 |
| Options available for future grants | 410380 |  |

---

As of March 31, 2026, the weighted average remaining contractual life of options outstanding is 3.3 years (2.4 years for options exercisable); the aggregate intrinsic value of options outstanding and options exercisable is $0.3 million and $0.0 million, respectively; and unrecognized compensation cost related to stock options outstanding aggregated $3.1 million.

Cash proceeds, tax benefits and intrinsic value related to stock options exercised during the March 31, 2026 and 2025 were as follows:

---

| | | |
|:---|:---|:---|
| (In thousands) | **March 31, 2026** | **March 31, 2025** |
| Cash proceeds from stock options exercised | $280 | $1077 |
| Tax benefits | 20 | 125 |
| Intrinsic value of stock options exercised | 160 | 840 |

---

There were no options granted during the March 31, 2026 and March 31, 2025.

Expected volatility is estimated based on the historic volatility of the Company's common stock. The expected term of the option is estimated based on historical data. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of the grant of the option and the dividend yield reflects the assumption that the dividend payout as authorized by the Board of Directors maintain its current payout ratio as a percentage of earnings.

In March 2022, Interparfums SA, our 72% owned French subsidiary, approved a plan to grant an aggregate of 88,400 shares of its stock to all Interparfums SA employees and corporate officers having more than six months of employment at grant date, subject to certain corporate performance conditions. The corporate performance conditions were met and therefore in June 2025,106,046 shares, adjusted for stock splits, were distributed.

The fair value of the grant had been determined based on the quoted stock price of Interparfums SA shares as reported by the Euronext on the date of grant. The aggregate cost of the grant of approximately $4.2 million was recognized as compensation cost on a straight-line basis over the requisite three and a quarter year service period.

------

***INTERPARFUMS, INC. AND SUBSIDIARIES***

**Notes to Consolidated Financial Statements**

In order to avoid dilution of the Company's ownership of Interparfums SA, all shares distributed pursuant to this plan were pre-existing shares of Interparfums SA, purchased in the open market by Interparfums SA. As of March 31, 2026 the Company acquired 106,046 shares at an aggregate cost of $4.5 million.

In December 2025, Interparfums SA, approved a new performance-based free share plan to grant an aggregate of 137,900 shares to all Interparfums SA employees and corporate officers who are employed as of the final vesting date of March 1, 2029, subject to certain corporate performance conditions. The fair value of the grant was determined based on the quoted stock price of Interparfums SA shares as reported by the Euronext on the date of the grant, adjusted for expected dividends over the vesting period and for performance conditions. Based on the expected retention rate and probability of achieving performance conditions, the total estimated expense for the plan is approximately $2.3 million (€2 million), recognized on a straight-line basis over the 3.25 year vesting period. In order to avoid dilution of the Company's ownership of Interparfums SA, all shares to be distributed pursuant to this plan will be pre-existing shares of Interparfums SA, purchased in the open market by Interparfums SA. During the 3 months ended March 31, 2026 and as of March 31, 2026, the Company acquired 56,264 shares at an aggregate cost of $1.5 million.

All share purchases and issuances have been classified as equity transactions on the accompanying balance sheet.

**9.** **<u>Net Income Attributable to Interparfums, Inc. Common Shareholders:</u>**

Net income attributable to Interparfums, Inc. per common share ("basic EPS") is computed by dividing net income attributable to Interparfums, Inc. by the weighted average number of shares outstanding. Net income attributable to Interparfums, Inc. per share assuming dilution ("diluted EPS"), is computed using the weighted average number of shares outstanding, plus the incremental shares outstanding assuming the exercise of dilutive stock options using the treasury stock method.

The reconciliation between the numerators and denominators of the basic and diluted EPS computations is as follows:

---

| | | |
|:---|:---|:---|
|  | **Three months ended** | **Three months ended** |
| (In thousands) | **March 31,** | **March 31,** |
|  | **2026** | **2025** |
| Numerator: |  |  |
| &nbsp;&nbsp;Net income attributable to Interparfums, Inc. | $43366 | $42492 |
| Denominator: |  |  |
| &nbsp;&nbsp;Weighted average shares | 32028 | 32121 |
| &nbsp;&nbsp;Effect of dilutive securities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock options |  | 53 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Denominator for diluted earnings per share | 32028 | 32174 |
| Earnings per share: |  |  |
| &nbsp;&nbsp;Net income attributable to |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interparfums, Inc. common shareholders: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic | $1.35 | $1.32 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted | $1.35 | $1.32 |

---

Not included in the above computations are the effect of antidilutive potential common shares which consist of outstanding options to purchase 0.18 million shares of common stock for the three months ended March 31, 2026 and 0.04 million shares of common stock for the three months ended March 31, 2025.

------

***INTERPARFUMS, INC. AND SUBSIDIARIES***

**Notes to Consolidated Financial Statements**

**10.** **<u>Segment and Geographic Areas:</u>**

The Company manufactures and distributes one product line, fragrances and fragrance related products. The Company manages its business in two segments, European based operations and United States based operations. The European based operations, assets and business operations are primarily conducted in France, and include the results and assets of Interparfums Luxury Brands, Inc., located in the United States. For United States based operations, assets and business operations are primarily conducted in the United States, and include the results and assets of Interparfums Italia Srl, located in Italy. Both European based operations and United States based operations primarily represent the sale of prestige brand name fragrances.

Information on the Company's operations by segments is as follows:

---

| | | | |
|:---|:---|:---|:---|
|  | **Three Months Ended March 31, 2026** | **Three Months Ended March 31, 2026** | **Three Months Ended March 31, 2026** |
|  | **United States<br> based operations** | **European<br> based operations** | **Total** |
| Net sales | $96136 | $252217 | $348353 |
| Eliminations (a) |  | (3468) | (3468) |
|  | 96136 | 248749 | 344885 |
| Less: (b) |  |  |  |
| Cost of sales | 39487 | 82120 |  |
| Eliminations (a) |  | (1361) |  |
| Segment gross margin | 56649 | 167990 | 224639 |
| Less: (b) |  |  |  |
| Advertising and Promotion | 14916 | 36661 |  |
| Employee related costs | 13494 | 19867 |  |
| Royalties | 8454 | 23452 |  |
| Other segment items (c) | 9190 | 24471 |  |
| Segment income from operations | $10595 | $63539 | $74134 |
| *Reconciliation:* |  |  |  |
| Interest expense |  |  | 1434 |
| Loss on foreign currency |  |  | 102 |
| Interest and investment income |  |  | (2318) |
| Other income |  |  | (290) |
| Income before income taxes |  |  | $75206 |

---

------

***INTERPARFUMS, INC. AND SUBSIDIARIES***

**Notes to Consolidated Financial Statements**

---

| | | | |
|:---|:---|:---|:---|
|  | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** |
|  | **United States<br> based operations** | **European<br> based operations** | **Total** |
| Net sales | $94345 | $247826 | $342171 |
| Eliminations (a) |  | (3352) | (3352) |
|  | 94345 | 244474 | 338819 |
| Less: (b) |  |  |  |
| Cost of sales | 38966 | 85382 |  |
| Eliminations (a) |  | (1506) |  |
| Segment gross margin | 55379 | 160598 | 215977 |
| Less: (b) |  |  |  |
| Advertising and Promotion | 15388 | 36140 |  |
| Employee related costs | 13865 | 18188 |  |
| Royalties | 7038 | 21023 |  |
| Other segment items (c) | 8627 | 20631 |  |
| Segment income from operations | $10461 | $64616 | $75077 |
| *Reconciliation:* |  |  |  |
| Interest expense |  |  | 1545 |
| Loss on foreign currency |  |  | 781 |
| Interest and investment loss (income) |  |  | (581) |
| Other expense (income) |  |  | (79) |
| Income before income taxes |  |  | $73411 |

---

(a) Eliminations of intercompany sales relate to European based operations products sold to United States based operations.

(b) The significant expense categories and amounts align with the segment-level information that is regularly provided to the chief operating decision maker.

(c) Other segment items for each reportable segment include expenses for professional services, travel and entertainment, rent, warehousing, shipping, depreciation and amortization, and other selling, general and administrative costs.

------

***INTERPARFUMS, INC. AND SUBSIDIARIES***

**Notes to Consolidated Financial Statements**

Other segment disclosures:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|  | **2026** | **2025** |
| Net income attributable to Interparfums, Inc.: |  |  |
| United States | $8422 | $8668 |
| Europe | 36524 | 35209 |
| Eliminations | (1580) | (1385) |
|  | $43366 | $42492 |
| Depreciation and amortization expense: |  |  |
| United States | $1478 | $1680 |
| Europe | 4321 | 4247 |
|  | $5799 | $5927 |
| Interest and investment (income) loss: |  |  |
| United States | $365 | $232 |
| Europe | 1953 | 349 |
|  | $2318 | $581 |
| Interest expense: |  |  |
| United States | $116 | $210 |
| Europe | 1318 | 1335 |
|  | $1434 | $1545 |
| Income tax expense: |  |  |
| United States | $1666 | $1712 |
| Europe | 16959 | 16449 |
| Eliminations | (122) | (153) |
|  | $18503 | $18008 |
| Additions to long-lived assets(a): |  |  |
| United States | $1408 | $170 |
| Europe | 1730 | 23765 |
|  | $3138 | $23935 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (a) Total long-lived assets include property, equipment and leasehold improvements, trademarks, licenses, and other intangible assets, and right-of-use assets.

---

| | | |
|:---|:---|:---|
|  | **March 31,** | **December 31,** |
|  | **2026** | **2025** |
| Total Assets: |  |  |
| &nbsp;&nbsp;&nbsp;United States | $345267 | $369871 |
| &nbsp;&nbsp;&nbsp;Europe | 1212956 | 1229174 |
| &nbsp;&nbsp;&nbsp;Eliminations | (15440) | (13797) |
|  | $1542783 | $1585248 |

---

------

***INTERPARFUMS, INC. AND SUBSIDIARIES***

---

| | |
|:---|:---|
| **I** **tem** **2** **:** | [**MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**](#TOC) |

---

**Forward Looking Information**

Statements in this report which are not historical in nature are forward-looking statements. Although we believe that our plans, intentions and expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such plans, intentions or expectations will be achieved. In some cases, you can identify forward-looking statements by forward-looking words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "should," "will" and "would" or similar words. You should not rely on forward-looking statements because actual events or results may differ materially from those indicated by these forward-looking statements as a result of a number of important factors. These factors include, but are not limited to, the risks and uncertainties discussed under the headings "Forward Looking Statements" and "Risk Factors" in Interparfums' annual report on Form 10-K for the fiscal year ended December 31, 2025, and the reports Interparfums files from time to time with the Securities and Exchange Commission ("SEC"). Interparfums does not intend to and undertakes no duty to update the information contained in this report.

**Overview**

We operate in the fragrance business, and manufacture, market and distribute a wide array of prestige fragrances and fragrance related products. We manage our business in two segments, European based operations and United States based operations. Certain prestige fragrance products are produced and marketed by our European based operations through our 72% owned subsidiary in Paris, Interparfums SA, which is also a publicly traded company as 28% of Interparfums SA shares trade on the Euronext.

We produce and distribute fragrance products through our European based operations primarily under license agreements with brand owners, and European based fragrance product sales represented approximately 72% of net sales for the three months ended March 31, 2026 and 2025. We have built a portfolio of prestige brands, which include Boucheron, Coach, Goutal, Jimmy Choo, Karl Lagerfeld, Kate Spade, Lacoste, Lanvin, Longchamp, Moncler, Montblanc, Off-White, Rochas, Solférino and Van Cleef & Arpels, whose products are distributed in over 120 countries around the world.

Through our United States based operations, we also produce and distribute fragrance and fragrance related products. United States based operations represented 28% of net sales for the three months ended March 31, 2026 and 2025. These fragrance products are sold primarily pursuant to license or other agreements with the owners of the Abercrombie & Fitch, Anna Sui, Donna Karan/DKNY, Emanuel Ungaro, Ferragamo, Graff, GUESS, Hollister, MCM, Oscar de la Renta and Roberto Cavalli brands.

Substantially all of our prestige fragrance brands are licensed from unaffiliated third parties, and our business is dependent upon the continuation and renewal of such licenses. With respect to the Company's largest brands, we license the Coach, Jimmy Choo, Montblanc, GUESS, Lacoste, Donna Karan/DKNY, and Ferragamo brand names.

As a percentage of net sales for the three months ended March 31, 2026 and 2025, product sales for the Company's largest brands represented 81% and 76%, respectively, with a split by brand as follows:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended**<br> **March 31,** | **Three Months Ended**<br> **March 31,** |
|  | **2026** | **2025** |
| Coach | 21% | 16% |
| Jimmy Choo | 18% | 19% |
| Montblanc | 16% | 14% |
| GUESS | 11% | 10% |
| Lacoste | 7% | 8% |
| Donna Karan/DKNY | 6% | 6% |
| Ferragamo | 2% | 3% |

---

------

***INTERPARFUMS, INC. AND SUBSIDIARIES***

For the three months ended March 31, 2026, Macy's, our top retail customer, accounted for approximately 12% of net sales. No one customer represented 10% or more of net sales for the three months ended March 31, 2025.

Quarterly sales fluctuations are influenced by the timing of new product launches as well as the third and fourth quarter holiday season. In certain markets where we sell directly to retailers, seasonality is more evident. We primarily sell directly to retailers in France, the United States, and Italy.

We grow our business in two distinct ways. First, we grow by adding new brands to our portfolio, through new licenses or other arrangements, or outright acquisitions of brands. Second, we grow through the introduction of new products and by supporting new and established products through advertising, merchandising and sampling, as well as phasing out underperforming products, so we can devote greater resources to those products with greater potential. The economics of developing, producing, launching and supporting products influence our sales and operating performance each year. The introduction of new products may have some cannibalizing effect on sales of existing products, which we take into account in our business planning.

Our business is not capital intensive, and it is important to note that we do not own manufacturing facilities. We act as a general contractor and source our needed components from our suppliers. These components are received and stored directly at our third party fillers or received at one of our distribution centers. For those components received at one of our distribution centers, based upon production needs, the components are subsequently sent to one of several third party fillers, which manufacture the finished product for us and then deliver them to one of our distribution centers.

As with any global business, many aspects of our operations are subject to influences outside our control. We believe we have a strong and well diversified brand portfolio with global reach and potential. As part of our strategy, we plan to continue to make investments behind fast-growing markets and channels to grow market share.

Our reported net sales are impacted by changes in foreign currency exchange rates as approximately 50% of net sales of our European based operations are denominated in U.S. dollars, while almost all costs of our European based operations are incurred in euro. We address certain financial exposures through a controlled program of risk management that includes the use of derivative financial instruments and primarily enter into foreign currency forward exchange contracts to reduce the effects of fluctuating foreign currency exchange rates.

**Recent Important Events**

Please see our discussion of Recent Important Events, which is incorporated by reference to Note 2 to the Consolidated Financial Statements contained in this Quarterly Report on Form 10-Q for the quarter ended March 31, 2026.

**Discussion of Critical Accounting Policies**

Information regarding our critical accounting policies can be found in our 2025 Annual Report on Form 10-K filed with the SEC.

------

***INTERPARFUMS, INC. AND SUBSIDIARIES***

**Results of Operations**

***Three Months Ended March 31, 2026 as Compared to the Three Months Ended March 31, 2025***

**Net Sales:**

---

| | | | |
|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** |
|  | **March 31,** | **March 31,** | **March 31,** |
| (in millions) | **2026** | **2025** | **% Change** |
| European based product sales | $252.2 | $247.8 | 2% |
| United States based product sales | 96.1 | 94.3 | 2% |
| Eliminations | (3.5) | (3.3) | n/a |
|  | $344.9 | $338.8 | 2% |

---

\*n/a = not applicable

Net sales for the three months ended March 31, 2026 increased 2% from the three months ended March 31, 2025. The average dollar/euro exchange rate for the current first quarter was 1.17 compared to 1.05 in the first quarter of 2025, resulting in a positive foreign exchange impact on net sales of 4.6% in the three months ended March 31, 2026 as compared to the prior year period.

For European based operations, sales in the three months ended March 31, 2026 increased 2%, compared to the corresponding period of the prior year, which included a 5.5% positive foreign exchange impact. Coach fragrance sales grew 30%, in the first quarter of 2026, following an 11% increase in the prior year period. This growth was driven by strong sell-in following the launches of new extensions within the *Coach Women* and *Coach Men* franchises, *Coach Cherry* and *Coach Platinum*, as well as sustained strong demand across most existing lines. Montblanc fragrance sales rose 14% in the first quarter of 2026, driven by the launch of *Legend Elixir*, the continued success of *Explorer Extreme*, and a lower sales base in last year's first quarter. We plan to launch a new extension for the *Explorer Extreme* line in the second half of the year to sustain the brand. While Jimmy Choo fragrance sales continue to grow in the United States, supported by the ongoing success of the *I Want Choo* franchise and the first quarter launch of Jimmy Choo *Man Parfum*, overall brand net sales declined 4% in the first quarter of 2026. This reflected a moderate downturn in certain European and Asian markets. Fragrance sales of Lacoste declined 12% in the first quarter of 2026 against a high base in the prior year period in which sales grew 30% behind a very successful innovation program as well as challenging market conditions primarily in Eastern Europe. We remain confident in the brand's medium and long-term potential, given recent and upcoming extensions in 2026 and planned blockbuster launches in 2027 and 2028.

For United States based operations, sales in the three months ended March 31, 2026 increased 2% compared to the corresponding period of the prior year, which included a 2.5% positive foreign exchange impact. GUESS fragrance sales rose 11% in the first quarter of 2026 supported by successful launches of new extension within the *Iconic* and *Seductive* pillars, *Iconic Sublime*, the newest men's fragrance that extends the franchise's strong momentum, and *Seductive Desire*, a bold new dual-gender fragrance duo. Following a successful first two years in our portfolio, Roberto Cavalli continued to generate robust results, achieving 32% sales growth during the first quarter of 2026. Growth was fueled by the latest innovation released during the quarter, including the *Just Cavalli Wild Heart* extension dual-gender duo, *Wild Pink* & *Wild Blue*, and *Verde Assoluto*, the newest fragrance within the *Uomo* pillar. Donna Karan/DKNY net sales declined by a modest 3% in the first quarter of 2026 off a strong sales base in the first quarter of 2025; however, sales of *Be Delicious Core* rebounded by 16% in the first quarter of 2026, compared to the prior year period, reflecting renewed consumer demand and strengthening momentum for the franchise. We expect sales to improve as the year progresses, driven by support for the new DKNY three-scent collection, *Be Delicious Latte*, and the new fragrance for the Donna Karan *Cashmere Collection*, *Cashmere & Rose Absolu*.

While the 2026 first quarter experienced a slight decline in organic sales, net sales grew overall, and we remain cautiously optimistic about the remainder of 2026. Looking ahead to 2027, we continue to be optimistic by the enhanced offerings within our current portfolio of brands, the introduction of new fragrances from recently acquired brands and licenses, and the selective pursuit of incremental brand opportunities. While the pace of growth in the market is starting to normalize closer to historical levels following massive growth seen over the past few years, the power of our diverse brand portfolio, in combination with our agile operating model, should help us gain market share.

------

***INTERPARFUMS, INC. AND SUBSIDIARIES***

---

| | | |
|:---|:---|:---|
| ***Net Sales to Customers by Region*** | **Three Months Ended** | **Three Months Ended** |
|  ***(In millions)*** | **March 31,** | **March 31,** |
|  | **2026** | **2025** |
| North America | $131.2 | $123.0 |
| Western Europe | 86.5 | 86.2 |
| Asia/Pacific | 46.6 | 50.3 |
| Central and South America | 38.2 | 31.0 |
| Eastern Europe | 22.4 | 25.6 |
| Middle East and Africa | 20.0 | 22.7 |
|  | $344.9 | $338.8 |

---

In the three months ended March 31, 2026, net sales in our largest market, North America, rose 7% as compared to the prior year period behind continued market growth, the launch of several extensions, in particular for Coach, as well as successful marketing and advertising investments, while sales in Western Europe remained flat behind slow consumer demand. Our sales in Asia/Pacific decreased by 7% driven by distribution changes we implemented in 2025 in South Korea and India, and softer consumer demand in Australia/New Zealand, which were partially compensated by strong growth in China. Central and South America net sales increased 23% due to the success of women's and men's Coach franchises and the strength of the Montblanc *Legend* line. Our net sales in Eastern Europe decreased 12% in the three months ended March 31, 2026 as compared to the prior year period driven by operational difficulties in certain countries, which disproportionately impacted Lanvin and Lacoste. Middle East and Africa net sales also declined 12% primarily due to recent intensification of the conflicts in those regions.

---

| | | |
|:---|:---|:---|
| ***Gross Profit Margin*** | **Three Months Ended** | **Three Months Ended** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(in millions) | **March 31,** | **March 31,** |
|  | **2026** | **2025** |
| **European based operations** |  |  |
| Net sales | $252.2 | $247.8 |
| Cost of sales | 82.1 | 85.4 |
| Gross profit margin | $170.1 | $162.4 |
| Gross profit margin as a percentage of net sales | 67.4% | 65.5% |
| **United States based operations**  |  |  |
| Net sales | $96.1 | $94.3 |
| Cost of sales | 39.5 | 38.9 |
| Gross profit margin | $56.6 | $55.4 |
| Gross profit margin as a percentage of net sales | 58.9% | 58.7% |

---

The Company's gross profit margin as a percentage of net sales was 65.1% for the three months ended March 31, 2026 as compared to 63.7% for the corresponding period of the prior year. The increase was the result of favorable segment, brand and channel mix as well as lower than expected destruction costs. These were partially offset by tariffs which represented an expense of $6 million in the three months ended March 31, 2026 as compared to the prior year period.

For European based operations, gross profit margin as a percentage of net sales was 67.4% for the three months ended March 31, 2026, respectively, as compared to 65.5% for the corresponding period of the prior year. The increase was the result of favorable brand and channel mix as well as lower than expected destruction costs. These were partially offset by tariffs which represented an expense of $4 million in the three months ended March 31, 2026 as compared to the prior year period.

------

***INTERPARFUMS, INC. AND SUBSIDIARIES***

For United States based operations, gross profit margin as a percentage of net sales remained flat at 58.9% for the three months ended March 31, 2026 respectively, as compared to 58.7% for the corresponding period of the prior year. Favorable brand and channel mix as well as lower than expected destruction costs were offset by tariffs which represented an expense of $2 million in the three months ended March 31, 2026 as compared to the prior year period.

Generally, we do not bill customers for shipping and handling costs, which are included in selling, general and administrative expenses in the consolidated statements of income. As such, our Company's gross profit may not be comparable to other companies, which may include these expenses as a component of cost of goods sold.

---

| | | |
|:---|:---|:---|
| ***Selling, general and administrative expenses*** | **Three Months Ended** | **Three Months Ended** |
|  ***(In millions)*** | **March 31,** | **March 31,** |
|  | **2026** | **2025** |
| **European based operations**  |  |  |
| Selling, general and administrative expenses | $104.4 | $96.0 |
| Selling, general and administrative expenses as a percentage of net sales | 41.4% | 38.7% |
| **United States based operations** |  |  |
| Selling, general and administrative expenses | $46.1 | $44.9 |
| Selling, general and administrative expenses as a percentage of net sales | 47.9% | 47.6% |

---

The Company's selling, general and administrative expenses as a percentage of net sales were 43.6% for the three months ended March 31, 2026 as compared to41.6% for the three months ended March 31, 2025. The increase in selling, general and administrative expenses as a percentage of net sales in the quarter resulted from royalty costs growing ahead of sales driven by unfavorable brand mix as well higher logistics costs related to supply chain transitions and channel mix.

For European based operations, selling, general and administrative expenses increased 8.8% for the three months ended March 31, 2026, respectively as compared to the corresponding period of the prior year, and represented 41.4% of net sales for the three months ended March 31, 2026, as compared to 38.7% for the three months ended March 31, 2025. The increase in expenses was largely driven by increases in employee related costs as we are building up our Korean subsidiary and higher logistics costs related to increased warehouse fees. Royalty costs also grew ahead of sales driven by unfavorable brand mix. For United States based operations, selling, general and administrative expenses increased 2.5% for the three months ended March 31, 2026 as compared to the corresponding period of the prior year, in line with sales increases, and represented 47.9% of net sales for the three months ended March 31, 2026, as compared to 47.6% for the three months ended March 31, 2025.

Promotion and advertising included in selling, general and administrative expenses aggregated $51.6 million for the three months ended March 31, 2026, respectively, as compared to $51.5 million for the corresponding period of the prior year and represented 15.0% of net sales for the three months ended March 31, 2026, respectively, as compared to15.2% for the corresponding period of the prior year. Promotion and advertising are integral parts of our industry, and we continue to invest heavily to support new product launches and to build brand awareness. We are also investing in line with anticipated sell out by our retailers, which we believe are higher than our reported sales. We believe that our promotion and advertising efforts have a beneficial effect on sales. As such, the Company is focused on increasing promotional and advertising spending to support the continued success of our brands. Long term, we continue to anticipate that on a full year basis, promotion and advertising expenditures will aggregate approximately 21% of net sales.

------

***INTERPARFUMS, INC. AND SUBSIDIARIES***

Royalty expense included in selling, general and administrative expenses aggregated $31.9 million for the three months ended March 31, 2026, respectively, as compared to $28.1 million for the corresponding period of the prior year. Royalty expense represented 9.3% of net sales for the three months ended March 31, 2026 as compared to8.3% of net sales for the corresponding periods of the prior year. This increase was primarily driven by unfavorable brand mix.

***Income from Operations***

As a result of the above analysis regarding net sales, gross profit margins and selling, general and administrative expenses, our operating margins aggregated 21.5% for the three months ended March 31, 2026, respectively, as compared to22.2% for the corresponding period of the prior year.

***Other Income and Expense***

Overall, other income and expense for the three months ended March 31, 2026, was a gain of $1.1 million as compared to a loss of $1.7 million in the corresponding prior year period. The main drivers of the change are discussed in more detail below. These include the positive impact of the change in foreign currency where we recognized a loss of only $0.1 million in the first three months of 2026 compared to a loss of $0.8 million in the first three months of 2025. Additionally, we had a gain on interest income related to cash and cash equivalents and short-term investments of $1.7 million and a reduction in interest expense on borrowings of $0.1 million.

Interest expense is primarily related to the financing of brand and licensing acquisitions, as well as our headquarters in Paris. Long-term debt including current maturities aggregated $157.3 million and $176.0 million as of March 31, 2026 and December 31, 2025, respectively. Interest expense was $1.4 million in the three months ended March 31, 2026 compared to $1.5 million in the prior year period.

We enter into foreign currency forward exchange contracts to manage exposure related to receivables from unaffiliated third parties denominated in a foreign currency and occasionally to manage risks related to future sales expected to be denominated in a foreign currency. Approximately 50% of net sales of our European based operations are denominated in U.S. dollars. Gains and losses in derivatives designated as hedges are accumulated in other comprehensive income and gains and losses in derivatives not designated as hedges are included in (gain) loss on foreign currency on the accompanying consolidated income statements. Such gains and losses were immaterial in the three months ended March 31, 2026 and 2025.

Interest and investment income represents interest earned on cash and cash equivalents and short-term investments and realized and unrealized gains and losses on marketable equity securities. Interest income was $1.6 million in the three months ended March 31, 2026 compared to $1.3 million in the prior year period. Additionally, we recognized gains on marketable equity securities of $0.7 million in the three months ended March 31, 2026 compared a loss of $0.7 million in the three months ended March 31, 2025.

***Income Taxes***

Our consolidated effective tax rate was 24.6% and 24.5% for the three months ended March 31, 2026 and 2025, respectively. The effective tax rate for European based operations remained flat at 25.4% for the three months ended March 31, 2026 as compared to 25.5% for the three months ended 2025. The effective tax rate for United States based operations was 19.7% for the three months ended March 31, 2026, as compared to 18.1% for the corresponding period of the prior year. Our effective tax rate for United States based operations differs from the 21% statutory rate in the United States as it is a blended rate across multiple jurisdictions, and takes into account benefits received from the exercise of stock options as well as deductions we are allowed for a portion of our foreign-derived deduction-eligible income, slightly offset by state and local taxes. Other than as discussed above, we did not experience any significant changes in tax rates, and none were expected in jurisdictions where we operate.

------

***INTERPARFUMS, INC. AND SUBSIDIARIES***

***Net Income***

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(In thousands) | **March 31,** | **March 31,** |
|  | **2026** | **2025** |
| Net income attributable to European based operations | $49861 | $48119 |
| Net income attributable to United States based operations | 8422 | 8668 |
| Eliminations | (1580) | (1384) |
| Net income | 56703 | 55403 |
| Less: Net income attributable to the noncontrolling interest | 13337 | 12911 |
| Net income attributable to Interparfums, Inc. | $43366 | $42492 |

---

Net income attributable to Interparfums, Inc. was $43.4 million for the three months ended March 31, 2026, respectively, as compared to $42.5 million for the corresponding period of the prior year.

Net income attributable to European based operations was $49.9 million for the three months ended March 31, 2026, as compared to $48.1 million for the corresponding period of the prior year, while net income attributable to United States based operations was $8.4 million for the three months ended March 31, 2026, as compared to $8.7 million the corresponding period of the prior year. The fluctuations in net income for both European based operations and United States based operations are directly related to the previous discussions pertaining to changes in sales, gross margin, and selling, general and administrative expenses.

The noncontrolling interest arises from our 72% owned subsidiary in Paris, Interparfums SA, which is also a publicly traded company, as 28% of Interparfums SA shares trade on the Euronext. Net income attributable to the noncontrolling interest is directly related to the profitability of our European based operations and aggregated 28% of European based operations net income for both the three months ended March 31, 2026 and 2025. Net profit margins attributable to Interparfums, Inc. for the three months ended March 31, 2026 and 2025 aggregated 12.6% and 12.5%, respectively.

**Liquidity and Capital Resources**

Our conservative financial tradition has enabled us to amass significant cash balances. As of March 31, 2026, we had $237.1 million in cash, cash equivalents and short-term investments, the majority of which are held in euros by our European based operations and is readily convertible into U.S. dollars. We have not experienced any liquidity issues to date, and do not expect any liquidity issues relating to such cash and cash equivalents and short-term investments.

As of March 31, 2026, working capital aggregated $692 million. Approximately 79% of the Company's total assets are held by European based operations, and approximately $285 million of trademarks, licenses and other intangible assets are also held by European based operations.

The Company is party to a number of licenses and other agreements for the use of trademarks and rights in connection with the manufacture and sale of its products expiring at various dates through 2049. In connection with most of these license agreements, the Company is subject to minimum annual advertising commitments, minimum annual royalties and other commitments. See Item 8. Financial Statements and Supplementary Data – Note 11 – Commitments in our 2025 annual report on Form 10-K, which is incorporated by reference herein. Future advertising commitments are estimated based on planned future sales for the license terms that were in effect at December 31, 2025, without consideration for potential renewal periods and do not reflect the fact that our distributors share our advertising obligations.

The Company hopes to continue to benefit from its strong financial position to potentially acquire one or more brands, either on a proprietary basis or as a licensee. In January 2026, we entered into long-term global licensing agreements for the creation, development and distribution of fragrances and fragrance related products under the David Beckham and Nautica brands, effective April 1, 2028 and January 1, 2030, respectively. In July 2025, our 72% owned French subsidiary, Interparfums SA, signed an exclusive fragrance license agreement with Longchamp running through December 31, 2036. Our rights under these licenses are subject to certain minimum advertising expenditures and royalty payments as are customary in our industry. The first launch under our Longchamp license is expected in 2027. In June 2025, our 72% owned French subsidiary, Interparfums SA, acquired all intellectual property rights relating to Maison Goutal held by Amorepacific Europe, which is operating the Goutal brand under an existing license agreement that expired on December 31, 2025, when Interparfums SA began commercial use of the fragrance brand. Additionally, in June 2025, we renewed the Coach license agreement for an additional five-year term, extending the license through June 30, 2031.

------

***INTERPARFUMS, INC. AND SUBSIDIARIES***

Cash provided by operating activities aggregated $0.1 million for the three months ended March 31, 2026 compared to cash used in operating activity of $7.4 million for the three months ended March 31, 2025. For the three months ended March 31, 2026, working capital items used $67.3 million in cash from operating activities, as compared to $70.0 million in the 2025 period. From a cash flow perspective, accounts receivables are up 6% from year end 2025. The balance is reasonable based on first quarter 2026 sales levels and seasonality of the business. Days' sales outstanding increased to 78 days, up from 74 days in the corresponding period of the prior year, driven by changes in our channel mix. Despite the increase, we are still seeing strong collection activity and do not anticipate any issues with collections of accounts receivable. From a cash flow perspective, inventory levels as of March 31, 2026 increased 7% from year end 2025. Despite the increase, we continue to drive inventory efficiencies and work to increase conversion of raw materials into finished goods, resulting in finished goods making up 64% of our inventory levels at March 31, 2026 as compared to 63% at March 31, 2025. Despite foreign exchange headwinds, our inventories are down significantly year over year with $370 million at March 31, 2026 compared to $396 million at March 31, 2025, translating to a reduction of 17 days inventory on hand.

Cash flows used in investing activities in 2026 are comprised of the net effect of purchases and sales of short-term investments. These investments consist of certificates of deposit with maturities greater than six months, marketable equity securities and other contracts. In the first quarter of 2026, our strong cash flow position has enabled us to increase our short-term investments by $23 million compared to the year ended December 31, 2025.

In March 2025, the Company paid approximately $19.7 million for the purchase of the Goutal trademark.

Our business is not capital intensive as we do not own any manufacturing facilities. On a full year basis, spend on tools and molds fluctuates depending on our new product development and is typically not material. Capital expenditures also include amounts for office fixtures, computer equipment, and industrial equipment needed at our distribution centers.

Cash flows used in financing activities in 2026 predominately reflect repayments of debt and payments of dividends to stockholders.

Our short-term financing requirements are expected to be met by available cash on hand at March 31, 2026, and by short-term credit lines provided by domestic and foreign banks. The principal credit facilities for 2026 consist of $45 million in unsecured revolving lines of credit provided by a consortium of domestic commercial banks and approximately $9.2 million (€8 million) in credit lines provided by a consortium of international financial institutions. There was $4.6 million of short-term borrowings outstanding pursuant to these facilities as of March 31, 2026 and $7.6 million outstanding as of March 31, 2025.

In February 2025, our Board of Directors authorized an annual dividend to $3.20 per share, and in 2026 our Board of Directors maintained the annual dividend at $3.20 per share. The next quarterly cash dividend of $0.80 per share is payable on June 30, 2026 to shareholders of record on June 15, 2026.

We believe that funds provided by or used in operations can be supplemented by our present cash position and available credit facilities, so that they will provide us with sufficient resources to meet all present and reasonably foreseeable future operating needs.

Inflation rates in the United States and foreign countries in which we operate did not have a significant impact on operating results for the three months ended March 31, 2026; however, we have already started to see the impacts of tariffs on our cost structure and had adjusted our pricing accordingly in 2025. We continue to monitor for potential inflationary impacts as our suppliers potentially adjust their pricing as well.

------

***INTERPARFUMS, INC. AND SUBSIDIARIES***

---

| | |
|:---|:---|
| **Item 3:** | [**QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**](#TOC) |

---

**General**

We address certain financial exposures through a controlled program of risk management that primarily consists of the use of derivative financial instruments. We primarily enter into foreign currency forward exchange contracts in order to reduce the effects of fluctuating foreign currency exchange rates. We do not engage in the trading of foreign currency forward exchange contracts or interest rate swaps.

**Foreign Exchange Risk Management** 

We periodically enter into foreign currency forward exchange contracts to hedge exposure related to receivables denominated in a foreign currency and to manage risks related to future sales expected to be denominated in a currency other than our functional currency. We enter into these exchange contracts for periods consistent with our identified exposures. The purpose of the hedging activities is to minimize the effect of foreign exchange rate movements on the receivables and cash flows of Interparfums SA, whose functional currency is the euro. All foreign currency contracts are denominated in currencies of major industrial countries and are with large financial institutions, which are rated as strong investment grade.

All derivative instruments are required to be reflected as either assets or liabilities in the balance sheet measured at fair value. Generally, increases or decreases in fair value of derivative instruments will be recognized as gains or losses in earnings in the period of change. If the derivative is designated and qualifies as a cash flow hedge, then the changes in fair value of the derivative instrument will be recorded in other comprehensive income.

Before entering into a derivative transaction for hedging purposes, we determine that the change in the value of the derivative will effectively offset the change in the fair value of the hedged item from a movement in foreign currency rates. Then, we measure the effectiveness of each hedge throughout the hedged period. Any hedge ineffectiveness is recognized in the income statement.

At March 31, 2026, we had foreign currency contracts in the form of forward exchange contracts of approximately USD $38 million with maturities of less than one year. We believe that our risk of loss as the result of nonperformance by any of such financial institutions is remote.

**Interest Rate Risk Management**

We mitigate interest rate risk by monitoring interest rates, and then determining whether fixed interest rates should be swapped for floating rate debt, or if floating rate debt should be swapped for fixed rate debt.

**Item 4.** [**CONTROLS AND PROCEDURES**](#TOC)

**Evaluation of Disclosure Controls and Procedures** 

Please see Item 9A. Controls and Procedures, "Evaluation of Disclosure Controls and Procedures" and "Remediation Plan," as contained in our 2025 annual report on Form 10-K as filed with the SEC ("2025 Annual Report"), which are incorporated by reference in this quarterly report. As stated in our 2025 Annual Report, we believe that the actions set forth under "Remediation Plan," will collectively remediate the material weaknesses identified. However, our material weaknesses will not be considered remediated until the controls operate for a sufficient period of time and management has concluded, through testing, that the related controls are operating effectively. We will continue to monitor the design and effectiveness of these and other processes, procedures, and controls and will make any further changes management deems appropriate. The above disclosure is applicable to the evaluation of our disclosure controls and procedures for the first quarter of 2026.

**Changes in Internal Control Over Financial Reporting** 

Except as described above, there has been no significant change in our internal control over financial reporting (as defined in Rule 13a-15(f) of the Securities Exchange Act of 1934) that occurred during the quarterly period covered by this report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.

------

***INTERPARFUMS, INC. AND SUBSIDIARIES***

[**Part II. Other Information**](#TOC)

**[Item 1A. Risk Factors](#)**[.](#)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Information regarding our Risk Factors can be found in our 2025 Annual Report on Form 10-K filed with the SEC.

---

| | |
|:---|:---|
| **Item** **2.** | [**Unregistered Sales of Equity Securities and Use of Proceeds**.](#TOC) |

---

Item (c).

In February 2025, our Board of Directors authorized the Company to continue repurchasing up to 130,000 shares throughout 2025, which was increased to 260,000 shares in April 2025. In February 2026, our Board of Directors authorized the Company to continue repurchasing up to 260,000 shares throughout 2026.

---

| | | | | |
|:---|:---|:---|:---|:---|
| Interparfums, Inc. Purchase of Common Stock | Interparfums, Inc. Purchase of Common Stock | Interparfums, Inc. Purchase of Common Stock | Interparfums, Inc. Purchase of Common Stock | Interparfums, Inc. Purchase of Common Stock |
| Period | Total Number of Shares Purchased | Average price paid per share | Total number of shares purchased as part of publicly announced plans or programs | Maximum number (or approximate dollar value) of shares that may yet be purchased under the plans or programs |
| January 1-31 | 46004 | $85.56 | 46004 | 213,996 shares |
| February 1-28 | 0 | n/a | 0 | 213,996 shares |
| March 1-31 | 0 | n/a | 0 | 213,996 shares |
| Total | 46004 | $85.56 | 46004 | 213,996 shares |

---

[**Item 5. Other Information**](#TOC)

Item (c). During the first quarter of 2026, no director or officer has adopted or terminated either any "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement," as such terms are defined in the applicable regulation.

Items 1. Legal Proceedings, 3. Defaults Upon Senior Securities and 4. Mine Safety Disclosures, are omitted as they are either not applicable or have been included in Part I.

------

***INTERPARFUMS, INC. AND SUBSIDIARIES***

[**Item 6. Exhibits.**](#TOC)

The following documents are filed herewith:

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;Exhibit No. | &nbsp;&nbsp;Description | &nbsp;&nbsp;Page Number |
| &nbsp;&nbsp;[31.1](ex311_1.htm) | &nbsp;&nbsp;[Certifications required by Rule 13a-14(a) of Chief Executive Officer](ex311_1.htm) | &nbsp;&nbsp;29 |
| &nbsp;&nbsp;[31.2](ex312_2.htm) | &nbsp;&nbsp;[Certifications required by Rule 13a-14(a) of Chief Financial Officer and Principal Accounting Officer](ex312_2.htm) | &nbsp;&nbsp;30 |
| &nbsp;&nbsp;[32.1](ex321_3.htm) | &nbsp;&nbsp;[Certification required by Section 906 of the Sarbanes-Oxley Act of Chief Executive Officer](ex321_3.htm) | &nbsp;&nbsp;31 |
| &nbsp;&nbsp;[32.2](ex322_4.htm) | &nbsp;&nbsp;[Certification required by Section 906 of the Sarbanes-Oxley Act of Chief Financial Officer and Principal Accounting Officer](ex322_4.htm) | &nbsp;&nbsp;32 |
| &nbsp;&nbsp;101 | &nbsp;&nbsp;Interactive data files |  |

---

------

***INTERPARFUMS, INC. AND SUBSIDIARIES***

[**<u>SIGNATURES</u>**](#TOC)

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized on the 5th day of May 2026.

---

| | |
|:---|:---|
|  | **INTERPARFUMS, INC.** |
| By: | /s/ Michel Atwood |
|  | Chief Financial Officer |

---

------

## Exhibit 31.1

***INTERPARFUMS, INC. AND SUBSIDIARIES***

**Exhibit 31.1**

**<u>CERTIFICATIONS</u>**

I, Jean Madar, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Interparfums, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) Designed such internal control over financial reporting, or caused such control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based upon such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth quarter in case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 5, 2026

---

| |
|:---|
| /s/ Jean Madar |
| Jean Madar, |
| Chief Executive Officer |

---

------

## Exhibit 31.2

***INTERPARFUMS, INC. AND SUBSIDIARIES***

**Exhibit 31.2**

I, Michel Atwood, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Interparfums, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) Designed such internal control over financial reporting, or caused such control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based upon such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth quarter in case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 5, 2026

---

| |
|:---|
| /s/ Michel Atwood |
| Michel Atwood |
| Chief Financial Officer and |
| Principal Accounting Officer |

---

------

## Exhibit 32.1

***INTERPARFUMS, INC. AND SUBSIDIARIES***

**Exhibit 32.1**

**CERTIFICATION**

The undersigned hereby certifies, in accordance with 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, in his capacity as an officer of Interparfums, Inc., that the Quarterly Report of Interparfums, Inc. on Form 10-Q for the period ended March 31, 2026, fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934 and that the information contained in such report fairly presents, in all material respects, the financial condition and results of operation of Interparfums, Inc.

---

| | | |
|:---|:---|:---|
| Date: May 5, 2026 | By: | /s/ Jean Madar |
|  |  | Jean Madar, |
|  |  | Chief Executive Officer |

---

A signed original of this written statement required by Section 906 has been provided to Interparfums, Inc. and will be retained by Interparfums, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

------

## Exhibit 32.2

***INTERPARFUMS, INC. AND SUBSIDIARIES***

**Exhibit 32.2**

**CERTIFICATION**

The undersigned hereby certifies, in accordance with 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, in his capacity as an officer of Interparfums, Inc., that the Quarterly Report of Interparfums, Inc. on Form 10-Q for the period ended March 31, 2026, fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934 and that the information contained in such report fairly presents, in all material respects, the financial condition and results of operation of Interparfums, Inc.

---

| | | |
|:---|:---|:---|
| Date: May 5, 2026 | By: | /s/ Michel Atwood |
|  |  | Michel Atwood |
|  |  | Chief Financial Officer and |
|  |  | Principal Accounting Officer |

---

A signed original of this written statement required by Section 906 has been provided to Interparfums, Inc. and will be retained by Interparfums, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.<br>

------